Johnson & Johnson raises 2026 guidance on strong Q3 sales
Johnson & Johnson reported Q3 2026 sales of $25.4 billion with 5.9% growth, citing the MedTech and Pharma portfolios. The company has raised its full-year sales and EPS guidance, although Q3 net earnings dropped sharply due to special charges.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed